Can family physicians help patients initiate basal insulin therapy successfully?: Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: Lessons for family practice from the Canadian INSIGHT trial

Canadian Family Physician

Volumn 54, Issue 4, 2008, Pages 550-558

  Harris, Stewart ^a   Yale, Jean François ^b,c   Dempsey, Ellen ^d   Gerstein, Hertzel ^e,f,g  

^a WESTERN UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d SANOFI   (France)

^e MCMASTER UNIVERSITY   (Canada)

^f Service of Endocrinology and Metabolism

^g Hamilton Health Sciences

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; LIPID; METFORMIN; ORAL ANTIDIABETIC AGENT;

ALGORITHM; ARTICLE; BEDTIME DOSAGE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN TREATMENT; LIPID BLOOD LEVEL; MEDICAL SPECIALIST; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, ORAL; ADULT; AGED; CANADA; CHRONOTHERAPY; DIABETES MELLITUS, TYPE 2; ENDOCRINOLOGY; FAMILY PRACTICE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 42349101184     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):S1-152.
3. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2006;29(Suppl 1):S4-42.
4. International Diabetes Federation. Global guideline for type 2 diabetes. Brussels, Belg: International Diabetes Federation; 2005. Available from: www.idf.org. Accessed 2006 April 17.
5. Jaakkimainen L, Biaju RS, Kopp A. Sources of physician care for people with diabetes. In: Hux JE, Booth G, Slaughter P, Laupacis A, editors. Diabetes in Ontario: an ICES practice atlas. Toronto, ON: Institute for Clinical Evaluative Sciences; 2003. p. 9.181-92.
6. Harris S, Stewart M, Brown JB, Wetmore S, Faulds C, Webster-Bogaert S, et al. Type 2 diabetes in family practice: room for improvement. Can Fam Physician 2003;49:778-85.
7. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999;22(3):403-8.
8. Worrall G, Freake D, Kelland J, Pickle A, Keenan T. Care of patients with type II diabetes: a study of family physicians' compliance with clinical practice guidelines. J Fam Pract 1997;44:374-81.
9. Toth EL, Majumdar SR, Guirguis LM, Lewanczuk RZ, Lee TZ, Johnson JA. Compliance with clinical practice guidelines for type 2 diabetes in rural patients. Treatment gaps and opportunities for improvement. Pharmacotherapy 2003;23:659-65.
10. Harris SB, Ekoé J-M, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in the Canadian primary care setting. Diabetes Res Clin Pract 2005;70:90-7.
11. Koro CE, Bowlin SJ, Boureouis N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27(1):17-20.
12. Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sahhan SS, Alexander CH. Adequacy of glycemic, lipid and blood pressure management for patients with diabetes in a managed care setting. Diabetes Care 2004;27(3):694-8.
13. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obesity 2002;26(Suppl 3):S18-24.
14. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995;26:57-65.
15. Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev 2002;18(Suppl 3):S42-9.
16. LeRoith D, Levetan CS, Hirsch IB, Riddle MC. Type 2 diabetes: the role of basal insulin therapy. J Fam Pract 2004;53(3):1-9.
17. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20(3):292-8.
18. Gerstein HF, Yale J-F, Harris SB, Issa M, Stewart J, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) study. Diabet Med 2006;23:736-42.
19. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. CMAJ 1998;159(Suppl 8):S1-29.
20. Houlden R, Ross S, Harris S, Yale J-F, Sauriol L, Gerstein HC. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral agent therapy in the management of type 2 diabetes: the Canadian INSIGHT study. Diabetes Res Clin Pract 2007;78(2):254-8.
21. Philips LS, Branch WT Jr, Cook CB, Doyle JP, Kebb IM, Gallina DL, et al. Clinical inertia. Ann Intern Med 2001;135:825-34.
22. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control. Do specialists differ from primary care physicians? Diabetes Care 2005;28(3):600-6.
23. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26(11):3080-6.